deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03920293

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis

Sponsor: Alexion Pharmaceuticals, Inc.

Conditions Generalized Myasthenia Gravis
Interventions Placebo Ravulizumab
Updated 25 times since 2019 Last updated: Apr 26, 2024 Started: Mar 12, 2019 Primary completion: May 11, 2021 Completion: May 25, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Generalized Myasthenia Gravis, this trial is completed. The trial is conducted by Alexion Pharmaceuticals, Inc. and has accumulated 25 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Apr 2022 · 6 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Apr 2023 · 10 months · monthly snapshot~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Jun 2024 · 7 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

25 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE3

  5. Nov 2023 — Jun 2024 [monthly]

    Completed PHASE3

▶ Show 20 earlier versions

  1. Sep 2023 — Nov 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Apr 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Jun 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Apr 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Oct 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  6. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  7. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  8. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  9. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  10. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  11. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  12. May 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  13. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE3

  14. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  15. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  16. Dec 2019 — Feb 2020 [monthly]

    Recruiting PHASE3

  17. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  18. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  19. Jun 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  20. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

    First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alexion Pharmaceuticals, Inc.
Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Amsterdam, Netherlands , Ann Arbor, United States , Arhus C, Denmark , Aurora, United States , Austin, United States , Baltimore, United States , Barcelona, Spain , Bergamo, Italy , Berlin, Germany and 88 more locations